La description :skip to main content profile about us board of directors management team founders shareholders leukotac® medical need leukotac® development what is leukotac®? pipeline r&d immuno-oncology elb021 e...
Server:nginx... X-Powered-By:PHP/7.0.31
L'adresse IP principale: 137.74.95.32,Votre serveur Hong Kong,Ma Yau Tong
ISP:Beyond Excellent Technology Ltd TLD:com Code postal:hk
Ce rapport est mis à jour en 07-Aug-2018
Created Date:
2013-03-28
Changed Date:
2017-03-20
Données techniques du elsalysbiotech.com
Geo IP vous fournit comme la latitude, la longitude et l'ISP (Internet Service Provider) etc. informations.
Notre service GeoIP a trouvé l'hôte elsalysbiotech.com.Actuellement, hébergé dans Hong Kong et son fournisseur de services est Beyond Excellent Technology Ltd .
Les informations d'en-tête HTTP font partie du protocole HTTP que le navigateur d'un utilisateur envoie à appelé nginx contenant les détails de ce que le navigateur veut et acceptera de nouveau du serveur Web.
MX preference = 0, mail exchanger = elsalysbiotech-com.mail.protection.outlook.com.
HtmlToText
skip to main content profile about us board of directors management team founders shareholders leukotac® medical need leukotac® development what is leukotac®? pipeline r&d immuno-oncology elb021 elb031 elb041 elb011 (ophthalmology) partners news & events latest news careers join elsalys search english français immunotherapy in actions the new wave of immunotherapy antibodies in cancers and rare haematological diseases elsalys biotech a clinical stage immuno-oncology company that designs and develops a new generation of therapeutic antibodies welcome to elsalys biotech elsalys biotech is a pharmaceutical company which develops new generation antibodies to modulate the immune system of patients with cancer or rare haematological diseases. its mission is at the heart of personalised and precision medicine where the ultimate goal is to increase the proportion of responders to new treatments. today elsalys biotech is conducting 5 proprietary development programs including leukotac®, an immunotherapy antibody that has recently demonstrated its clinical superiority in phase 3 in an orphan disease with very poor prognosis: steroid-resistant acute graft-versus-host disease. the company is acting today in 3 main medical fields : acute graft-vs-host disease immuno-oncology ophthalmology (license option) new updates discover our latest news regarding our pipeline, our partnerships and more view more news new studies confirm anti-cd160 antibodies are potential therapeutics for ophthalmic diseases mon, 07/02/2018 - 15:00 - fri, 07/02/2021 - 15:30 efficacy and safety are consistently demonstrated in several in vivo preclinical models anti-cd160 is a potent inhibitor of ocular v read more elsalys biotech announces the registration of its document de base in the context of its proposed initial public offering on the paris euronext growth® market fri, 04/20/2018 - 08:30 not to be distributed directly or indirectly in the united states, canada, australia or japan read more leukotac® takes next step in paediatric acute steroid-resistant gvhd thu, 04/05/2018 - 09:00 elsalys biotech plans to submit to the european medicines agency before summer 2018 a paediatric investigation plan (pip) proposing to c read more stay in touch with our latest news subcribe to our newsletter subscribe now contactez nous headquarters, r&d;, shipping address : elsalys biotech sa, 317 avenue jean jaurès, 69007 lyon administrative site : elsalys biotech sa, pépinière de hautepierre 8 avenue dante, cs 70033 f-67087 strasbourg contact@elsalysbiotech.com +33 (0)4 37 28 73 00 raccourcis about us leukotac® r&d pipeline news & events careers contact us legal notice copyright 2018 elsalys biotech sa
Whois est un protocole qui permet d'accéder aux informations d'enregistrement.Vous pouvez atteindre quand le site Web a été enregistré, quand il va expirer, quelles sont les coordonnées du site avec les informations suivantes. En un mot, il comprend ces informations;
For more information on Whois status codes, please visit https://icann.org/epp
NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.
TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.
The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.
REGISTRAR OVH
SERVERS
SERVER com.whois-servers.net
ARGS domain =elsalysbiotech.com
PORT 43
TYPE domain RegrInfo DOMAIN
NAME elsalysbiotech.com
CHANGED 2017-03-20
CREATED 2013-03-28
STATUS clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Nous utilisons des cookies pour personnaliser votre expérience sur notre site. En poursuivant votre navigation, vous acceptez cette utilisation. Apprendre encore plus
elsalysbiotech.com rapport :
Visitez le site